Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals
- PMID: 23591634
- PMCID: PMC3693854
- DOI: 10.1097/QAI.0b013e318295eb1d
Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals
Abstract
Objective: To determine the association among bone mineral density (BMD), inflammatory markers, and alterations in fat and lean mass in untreated HIV-infected individuals.
Design: Cross-sectional analysis of antiretroviral therapy-naive persons enrolled into a randomized clinical trial.
Methods: Dual-energy x-ray absorptiometry for BMD and lean and fat mass and a laboratory assessment were performed. Soluble biomarkers included adipocytokines (leptin and adiponectin), inflammatory markers (high-sensitivity C-reactive protein and interleukin 6), and markers related to bone metabolism [osteoprotegerin (OPG)], receptor activator of nuclear factor κB ligand. BMD at the lumbar spine, total hip, and femoral neck was expressed as a Z score (number of standard deviations away from age-, race-, and sex-matched reference population).
Results: Three hundred thirty-one subjects had a median (Q1, Q3) age of 36 (28, 45) years, were 89% men, and 44% white. The prevalence of low BMD (Z score ≤ -2 at any of the 3 sites) was 10%. No associations were detected between Z scores and high-sensitivity C-reactive protein, interleukin 6, or receptor activator of nuclear factor κB ligand (P ≥ 0.1). In a linear model adjusting for age, gender, race, and total fat mass, lower lumbar spine Z scores were associated with lower total lean mass, higher serum adiponectin, and lower OPG. Results at the total hip or femoral neck were similar.
Conclusions: Among antiretroviral therapy-naive HIV-infected individuals, lower BMD was associated with lower lean mass, higher adiponectin, and lower OPG, but not HIV disease variables or any of the inflammatory markers. These findings may have implications for bone metabolism in untreated HIV, in which hypoadiponectinemia and higher OPG may mitigate bone loss.
Conflict of interest statement
Dr Brown has served as a consultant for BMS, GSK, Merck, Abbott, Gilead, ViiV Healthcare and has received research funding from Merck and GSK. Dr. Currier has served as a consultant for Gilead and has received research funding from Merck. Dr. Murphy has served as a consultant for Gilead and serves on a Data Safety Monitoring Board for Gilead. Dr Stein serves on a Data Safety Monitoring Board for Abbott, Lilly, and Takeda. Dr McComsey has served as a consultant or received research grants from BMS, Pfizer, and GSK. Dr Ribaudo and Ms Chen and Rothenberg have no Duality of Interest disclosures.
Figures
References
-
- Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22:465–75. - PubMed
-
- Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165–74. - PubMed
-
- Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis. 2011;52:1061–68. - PubMed
-
- Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Obel N. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS. 2012;26:285–93. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
- UM1 AI069501/AI/NIAID NIH HHS/United States
- AI56933/AI/NIAID NIH HHS/United States
- UM1 AI069471/AI/NIAID NIH HHS/United States
- AI69471/AI/NIAID NIH HHS/United States
- UM1 AI068634/AI/NIAID NIH HHS/United States
- HL095132/HL/NHLBI NIH HHS/United States
- AI068636/AI/NIAID NIH HHS/United States
- U01 AI068636/AI/NIAID NIH HHS/United States
- AI068634/AI/NIAID NIH HHS/United States
- UM1 AI069428/AI/NIAID NIH HHS/United States
- K24 AI056933/AI/NIAID NIH HHS/United States
- R01 HL095126/HL/NHLBI NIH HHS/United States
- R01 HL095132/HL/NHLBI NIH HHS/United States
- HL095126/HL/NHLBI NIH HHS/United States
- UM1 AI069465/AI/NIAID NIH HHS/United States
- U01 AI069471/AI/NIAID NIH HHS/United States
- U01 AI068634/AI/NIAID NIH HHS/United States
- UM1 AI068636/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
